Any indication that results are positive will see Sarepta jump on ANP to compliment their existing DMD drug Eteplirsen which only work with 13% of DMD patients. ATL1102 can be used to reduce inflammation in all DMD patients and for other conditions... we should also be expecting to hear soon about the Phase 11b European trial for ATL1102 which will be run in parallel and the ATL1103 EAP. Plenty of announcements about to drop..
- Forums
- ASX - By Stock
- DMD Phase 2 Results in Q4 = Potential 5000% Gem
Any indication that results are positive will see Sarepta jump...
-
- There are more pages in this discussion • 240 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.2¢ |
Change
0.002(2.50%) |
Mkt cap ! $73.92M |
Open | High | Low | Value | Volume |
8.1¢ | 8.5¢ | 8.1¢ | $145.4K | 1.739M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 69272 | 8.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.4¢ | 71037 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 69272 | 0.082 |
1 | 149432 | 0.081 |
2 | 127625 | 0.080 |
1 | 3600 | 0.079 |
2 | 250000 | 0.078 |
Price($) | Vol. | No. |
---|---|---|
0.084 | 71037 | 1 |
0.086 | 480000 | 3 |
0.087 | 400000 | 1 |
0.088 | 417000 | 3 |
0.089 | 228000 | 3 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online